Uni-Bio's osteoporosis candidate achieves phase III endpoint
SHANGHAI – Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in postmenopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial. Uni-PTH could be considered a biosimilar of Forteo (teriparatide, Eli Lilly and Co.), but since China has no pathway to prove biosimilarity, Uni-Bio took the drug through its paces as if it were a new drug.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter